IPSC News and Press, Century Therapeutics Inc. From 02/22/24

2024-02-22 13:10:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips You get what you pay for and that applies to under-$10 stocks. In many if not most cases, you’re dealing with speculative ideas that have little chance of swinging higher. Still, a handf...

2024-02-01 12:36:15 ET Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a com...

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the manag...

– Data presented at 65 th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable compl...

2023-12-06 15:42:16 ET A Philadelphia-based %Biotech company stole the show on Wednesday after it was announced that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101 in patients w...

2023-12-06 08:24:39 ET Century Therapeutics ( NASDAQ: IPSC ) gained over 8% premarket on Wednesday after the U.S. Food and Drug Administration cleared its investigational new drug (IND) for CNTY-101 in systemic lupus erythematosus (SLE). CNTY-101 is an investigational ce...

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a confe...

– Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication – – Company plans to initiate the Phase 1 clinical trial in the fi...

PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in a firesid...

2023-11-09 13:26:01 ET More on Century Therapeutics Century Therapeutics appoints Brent Pfeiffenberger as Chief Executive Officer JP Morgan cuts Century Therapeutics to neutral, cites lengthy data timeline Seeking Alpha’s Quant Rating on Century Therapeutics ...